Skip to main content
. Author manuscript; available in PMC: 2016 Oct 1.
Published in final edited form as: Immunogenetics. 2015 Sep 2;67(10):547–561. doi: 10.1007/s00251-015-0864-z

Table 2.

SNPs associated with more than one rubella-specific immune response outcome after MMR vaccination.

Cohort SNP ID Chromosome
/ Position
Gene Location Immune
Measure
N Genotype No. Immune Response
Outcome (IQR)
P Value Immune
Measure
N Genotype No. Immune Response
Outcome (IQR)
P Value
Rubella
Vaccine
Study
rs4682233 3/ 1.11×108 PVRL3 Intron Secreted
IL-6
(ng/µl)
969 AA
AG
GG
953
16
0
3609.7 (3049.2, 4006.3)
3372.2 (1952.7, 4094.1)
0.000675 Secreted
IFN-γ
(ng/µl)
969 AA
AG
GG
953
16
0
6.2 (1.5, 20.2)
3.7 (−5.8, 10.7)
0.000498
Rubella
Vaccine
Study
rs72935984 3/ 1.11×108 PVRL3 Intron Secreted
IL-6
(ng/µl)
962 CC
CA
AA
944
18
0
3609.8 (3048.0, 4007.3)
3608.4 (2134.9, 4123.8)
0.001363 Secreted
IFN-γ
(ng/µl)
962 CC
CA
AA
944
18
0
6.2 (1.5, 20.0)
5.4 (−0.4, 27.3)
0.004264
Rubella
Vaccine
Study
rs75054607
+NA
3/ 1.11×108 PVRL3 Intron Secreted
IFN-γ
(ng/µl)
969 AA
AG
GG
946
22
1
6.1 (1.5, 19.7)
11.6 (3.9, 33.6)
508.8 (508.8, 508.8)
0.000028 NA
(NT50)
1029 AA
AG
GG
1004
23
2
56.6 (34.6, 93.9)
112.5 (65.5, 159.4)
192.1 (31.2, 353.0)
0.001575
Rubella
Vaccine
Study
rs76464851
+NA
3/ 1.11×108 PVRL3 Intron Secreted
IFN-γ
(ng/µl)
969 AA
AG
GG
946
22
1
6.1 (1.5, 19.7)
11.6 (3.9, 33.6)
508.8 (508.8, 508.8)
0.000028 NA
(NT50)
1029 AA
AG
GG
1004
23
2
56.6 (34.6, 93.9)
112.5 (65.5, 159.4)
192.1 (31.2, 353.0)
0.001575
Rubella
Vaccine
Study
rs78157313
+NA
3/ 1.11×108 PVRL3 Intron Secreted
IFN-γ
(ng/µl)
967 AA
AG
GG
944
22
1
6.1 (1.5, 19.8)
11.6 (3.9, 33.6)
508.8 (508.8, 508.8)
0.000029 NA
(NT50)
1027 AA
AG
GG
1002
23
2
56.6 (34.6, 93.8)
112.5 (65.5, 159.4)
192.1 (31.2, 353.0)
0.001575
Rubella
Vaccine
Study
rs72937914
+IFN-γ
3/1.11 ×108 PVRL3 Intron Secreted
IL-6
(ng/µl)
969 AA
AC
CC
942
27
0
3612.3 (3056.4, 4008.4)
2917.9 (2076.4, 4064.3)
0.000386 Secreted
IFN-γ
(ng/µl)
969 AA
AC
CC
942
27
0
6.1 (1.5, 19.9)
6.1 (−0.4, 27.3)
0.040073
Rubella
Vaccine
Study
rs10433385
+IFN-γ
3/1.11 ×108 PVRL3 Intergenic Secreted
IL-6
(ng/µl)
968 AA
AG
GG
929
36
3
3613.2 (3056.4, 4020.6)
3398.5 (2754.5, 3870.5)
2717.6 (2617.3, 4306.3)
0.008086 Secreted
IFN-γ
(ng/µl)
968 AA
AG
GG
929
36
3
6.3 (1.6, 20.8)
3.5 (0.1, 7.7)
3.4 (2.6, 16.6)
0.012882
Rubella
Vaccine
Study
rs78545860
+IFN-γ
3/1.11×108 PVRL3 Intergenic Secreted
IL-6
(ng/µl)
969 AA
AG
GG
930
36
3
3614.0 (3056.4, 4020.6)
3398.5 (2754.5, 3870.5)
2717.6 (2617.3, 4306.3)
0.008063 Secreted
IFN-γ
(ng/µl)
969 AA
AG
GG
930
36
3
6.3 (1.6, 20.8)
3.5 (0.1, 7.7)
3.4 (2.6, 16.6)
0.012874
Rubella
Vaccine
Study
rs11820364
+NA
11/1.2×108 PVRL1 Intron Secreted
IL-6
(ng/µl)
969 GG
GA
AA
953
15
1
3595.6 (3036.5, 4000.4)
4328.9 (3759.0, 4494.6)
2271.6 (2271.6, 2271.6)
0.000102 NA
(NT50)
1029 GG
GA
AA
1010
18
1
57.4 (34.9, 95.3)
67.3 (32.5, 126.5)
75.8 (75.8, 75.8)
0.00822
Rubella
Vaccine
Study
rs61247604 11/1.2×108 PVRL1 Intron Secreted
IL-6
(ng/µl)
968 GG
GA
AA
956
12
0
3596.0 (3037.7, 4003.1)
4178.1 (3605.9, 4384.3)
0.000332 NA
(NT50)
1028 GG
GA
AA
1015
13
0
57.4 (34.8, 95.8)
63.1 (36.2, 74.5)
0.000477
Rubella
Vaccine
Study
rs73571285*
+IFN-γ
11/1.2×108 PVRL1 Intron Secreted
IL-6
(ng/µl)
969 AA
AG
GG
953
14
2
3600.2 (3049.7, 4003.7)
4011.0 (2630.3, 4439.8)
−450.2 (−957.3, 56.9)
0.000144 Secreted
IFN-γ
(ng/µl)
969 AA
AG
GG
953
14
2
6.2 (1.5, 20.0)
4.8 (−0.9, 62.3)
−51.9 (−60.5, −43.3)
0.022627
Rubella
Vaccine
Study
rs73571287*
+IFN-γ
11/1.2×108 PVRL1 Intron Secreted
IL-6
(ng/µl)
968 GG
GA
AA
959
8
1
3598.9 (3043.4, 4003.9)
4011.0 (1079.8, 4310.4)
56.9 (56.9, 56.9)
9×10−7 Secreted
IFN-γ
(ng/µl)
968 GG
GA
AA
959
8
1
6.2 (1.5, 20.2)
3.7 (−1.1, 38.4)
−43.3 (−43.3, −43.3)
0.02229
Rubella
Vaccine
Study
rs79849521
++
11/1.2×108 PVRL1 Intron Secreted
IL-6
(ng/µl)
969 GG
GA
AA
959
10
0
3598.9 (3036.5, 4003.9)
4099.9 (3356.6, 4328.9)
0.026416 NA
(NT50)
1029 GG
GA
AA
1018
11
0
57.4 (34.9, 95.7)
63.1 (33.4, 75.8)
0.004395
Rubella
Vaccine
Study
rs4936489
++
11/1.2×108 PVRL1 Intergenic Secreted
IL-6
(ng/µl)
968 GG
GA
AA
936
31
1
3605.0 (3041.1, 4005.1)
3514.8 (2803.7, 4126.2)
3696.9 (3696.9, 3696.9)
0.042337 NA
(NT50)
1028 GG
GA
AA
992
35
1
57.4 (34.7, 95.2)
65.5 (41.0, 101.3)
77.3 (77.3, 77.3)
0.03046
Rubella
Vaccine
Study
rs73578845+
NA
11/1.19×108 PVRL1 Intergenic Secreted
IL-6
(ng/µl)
969 GG
GC
CC
956
11
2
3596.0 (3041.1, 4003.1)
4078.1 (2299.1, 4439.8)
4099.9 (3970.0, 4229.9)
0.000315 NA
(NT50)
1029 GG
GC
CC
1015
12
2
57.4 (34.6, 95.4)
62.5 (52.7, 112.3)
116.5 (74.5, 158.6)
0.037341
Rubella
Vaccine
Study
rs2291842
+NA
11/5719667 TRIM2
2
Coding Secreted
IFN-γ
(ng/µl)
969 AA
AG
GG
639
285
45
5.9 (1.5, 19.9)
6.1 (1.9, 18.0)
11.5 (2.7, 42.5)
0.014516 NA
(NT50)
1029 AA
AG
GG
683
299
47
56.6 (34.6, 95.7)
58.9 (35.1, 94.8)
61.0 (34.9, 97.4)
0.029181
Rubella
Vaccine
Study
rs2291842
+NA
11/5719667 TRIM2
2
Coding Secreted
IL-6
(ng/µl)
969 AA
AG
GG
639
285
45
3619.8 (3056.4, 4002.4)
3595.8 (3024.7, 4038.5)
3350.8 (3025.7, 3868.0)
0.002321 NA
(NT50)
1029 AA
AG
GG
683
299
47
56.6 (34.6, 95.7)
58.9 (35.1, 94.8)
61.0 (34.9, 97.4)
0.029181
Rubella
Vaccine
Study
rs2291842
+IFN-γ
11/5719667 TRIM2
2
Coding Secreted
IL-6
(ng/µl)
969 AA
AG
GG
639
285
45
3619.8 (3056.4, 4002.4)
3595.8 (3024.7, 4038.5)
3350.8 (3025.7, 3868.0)
0.002321 Secreted
IFN-γ
(ng/µl)
969 AA
AG
GG
639
285
45
5.9 (1.5, 19.9)
6.1 (1.3, 18.0)
11.5 (2.7, 42.5)
0.014516
Rubella
Vaccine
Study
rs962859~
+IFN-γ
21/34648123 IL10RB Intron Secreted
IL-6
(ng/µl)
954 AA
AC
CC
323
483
148
3660.3 (3064.3, 4061.3)
3569.1 (3023.7, 4000.9)
3533.8 (3066.0, 3900.4)
0.008451 Secreted
IFN-γ
(ng/µl)
954 AA
AC
CC
323
483
148
6.9 (1.8, 22.8)
4.9 (1.2, 18.2)
7.5 (2.5, 21.4)
0.027823
Rubella
Vaccine
Study
rs2284552~
+IFN-γ
21/34644082 IL10RB Intron Secreted
IL-6
(ng/µl)
968 CC
CA
AA
600
321
47
3535.6 (2995.2, 3975.5)
3668.8 (3160.0, 4044.1)
3666.1 (3064.3, 4150.4)
7.89×10−5 Secreted
IFN-γ
(ng/µl)
968 CC
CA
AA
600
321
47
5.9 (1.2, 19.2)
6.2 (1.9, 21.7)
7.9 (1.6, 30.7)
0.018961
Rubella
Vaccine
Study
rs5030728
++
9/1.2×108 TLR4 Intron Secreted
IL-6
(ng/µl)
965 GG
GA
AA
489
398
78
3619.4 (3066.3, 4016.0)
3597.3 (3015.3, 3984.0)
3569.5 (2943.2, 4033.6)
0.018059 Secreted
IFN-γ
(ng/µl)
965 GG
GA
AA
489
398
78
5.5 (0.8, 19.7)
6.4 (1.9, 20.0)
6.5 (1.4, 25.2)
0.037292
Rubella
Vaccine
Study
rs2770150
+IFN-γ
9/1.2×108 TLR4 Intergenic Secreted
IL-6
(ng/µl)
968 AA
AG
GG
516
389
63
3615.4 (3064.5, 4005.1)
3600.2 (3018.3, 4008.4)
3542.9 (2943.2, 4085.3)
0.01256 Secreted
IFN-γ
(ng/µl)
968 AA
AG
GG
516
389
63
5.9 (1.1, 20.0)
6.3 (1.7, 19.2)
6.6 (1.1, 27.5)
0.017476
Rubella
Vaccine
Study
seq-
rs112723153
+IFN-γ
19/45178636 PVR Intron Secreted
IL-6
(ng/µl)
969 GG
GA
AA
961
8
0
3609.8 (3049.2, 4008.4)
2936.2 (2438.8, 3855.6)
0.011401 Secreted
IFN-γ
(ng/µl)
969 GG
GA
AA
961
8
0
6.1 (1.5, 20.0)
10.4 (0.3, 34.5)
0.041896
Rubella
Vaccine
Study
rs2229857~
+IFN-γ
1/1.55 ×108 ADAR Coding Secreted
IL-6
(ng/µl)
968 GG
GA
AA
505
374
89
3595.6 (3058.5, 4006.3)
3594.7 (3036.5, 4033.3)
3732.8 (3023.6, 3969.3)
0.000435 Secreted
IFN-γ
(ng/µl)
968 GG
GA
AA
505
374
89
6.0 (1.4, 20.0)
5.9 (1.5, 19.2)
8.4 (2.3, 22.1)
0.01358
Rubella
Vaccine
Study
rs3870968
+IFN-γ
6/29647149 ZFP57 Intron Secreted
IL-6
(ng/µl)
969 CC
CA
AA
866
102
1
3619.6 (3038.9, 4024.9)
3523.0 (3032.0, 3900.6)
3643.5 (3643.5, 3643.5)
0.006571 Secreted
IFN-γ
(ng/µl)
969 CC
CA
AA
866
102
1
5.9 (1.3, 19.2)
9.0 (3.2, 38.2)
16.1 (16.1, 16.1)
0.018177
Rubella
Vaccine
Study
rs469483~
+IFN-γ
21/42818515 MX1 Intron Secreted
IL-6
(ng/µl)
969 AA
AG
GG
308
485
176
3528.1 (2975.4, 3968.9)
3641.8 (3064.3, 4080.6)
3598.0 (3096.5, 3975.8)
0.002902 Secreted
IFN-γ
(ng/µl)
969 AA
AG
GG
308
485
176
5.0 (0.9, 18.5)
6.6 (1.8, 21.8)
6.4 (1.6, 19.5)
0.019999
Rubella
Vaccine
Study
rs2393657
++
6/26457688 BTN2A
1/BTN3
A3
Intergenic Secreted
IL-6
(ng/µl)
961 CC CA AA 854
107
0
3619.9 (3064.3, 4023.2)
3398.9 (2750.9, 3832.4)
0.031523 Secreted
IFN-γ
(ng/µl)
961 CC
CA
AA
854
107
0
6.2 (1.6, 20.8)
6.1 (0.4, 15.2)
0.034371

Abbreviations: NA-neutralizing antibody; SNP ID-single nucleotide polymorphism identification; IL-interleukin; IFN-interferon; IQR-interquartile range; NT50-neutralizing titer; A-Adenine; C-Cytosine; G-Guanine; No.-number

Negative values indicate that the unstimulated secretion levels were higher than the rubella virus-stimulated secretion levels.

*

Loss of significant association when homozygous minor allele genotype (observed only in few subjects) was excluded from analysis

+One phenotype failed to remain significantly associated with genotype as determined by having a q-value greater than 0.1.

++Two phenotypes failed to remain significantly associated with genotype as determined by having a q-value greater than 0.1.

~IL-6 remained significantly associated with genotype as determined by having a q-value greater than 0.1 in the Caucasian subset.